Financial Performance
5Y price score: 77
The price score is a basic measure of the stock's performance against the S&P 500 Index over a five-year period.
A score of 100 indicates that the stock did as well as the S&P 500 Index.
A score below 100 means the stock underperformed the index, while a score above 100 means it outperformed the S&P 500.
10Y return: 149.6%
%
ㅤ
By default your notes are visible only to you.
184.6
52-week range
281.0
Your model inputs
Your fair value & Margin of safety
To calculate fair value based on cost of capital and terminal growth assumptions above, please select free cash flow forecast.
Forecast:
Valuation
Free Cash Flow Yield
3 %
Dividend Yield TTM
2.1 %
Market cap $
$ 618,091
Price / Earnings TTM
29.7
Price / Book TTM
7.4
PEG TTM
0.3
Earnings growth and return
LTM
5YR
10YR
Total return (price & dividends)
37.9 %
73.9 %
149.6 %
Free cash flow per share growth
35.5 %
7.3 %
44.2 %
Earnings per share growth
(0.9) %
100.2 %
101.3 %
Founded: 1,886
Employees: 138,100
Business Summary:
Q&A
Contribute
By providing well-researched and detailed answer you increase your chance of becoming Top Contributor. TopFunds is free for all top contributors. Learn more
Latest Earnings Call Takeaways
2026 Q2 (Jul 15, 2026)
1) Strategy & Leadership
- Joaquin Duato, CEO, emphasized 2026 as a year of accelerated growth, reporting strong Q2 results and raised guidance.
- The company has 28 products generating over $1 billion in annual sales, showcasing a robust portfolio and pipeline.
- Johnson & Johnson aims to be the number one oncology company by 2030, with projected sales exceeding $50 billion.
2) Financial & Segment Results
- Q2 2026 worldwide sales reached $25.3 billion, a 5.6% increase YoY, with operational growth of 6.8% in Innovative Medicine.
- Net earnings were $5.5 billion, with diluted EPS of $2.27. Adjusted EPS increased to $2.90, up 4.7% YoY.
- Key growth drivers included:
- Oncology: DARZALEX grew 17.6%, CARVYKTI 47.7%, and TECVAYLI 56.1%.
- Immunology: TREMFYA surged 71%, while STELARA declined 55.7% due to biosimilar competition.
- MedTech: Sales of $8.9 billion grew 3.6%, with notable performance in cardiovascular and surgery segments.
3) Problems / Headwinds
- STELARA's decline impacted overall growth, contributing to a 460 basis point headwind.
- Abiomed's growth slowed due to increased physician selectivity and a recent neutral clinical trial affecting procedure volumes.
- Competitive pressures in MedTech, particularly in electrophysiology, contributed to lower-than-expected growth.
4) Operational or Product Plans
- New product launches, including ICOTYDE and INLEXZO, are expected to drive future growth, with ICOTYDE showing strong early uptake.
- The company plans to acquire Firefly Bio to enhance its oncology pipeline.
- Upcoming catalysts include FDA approvals for several products and continued expansion in the robotics segment with OTTAVA and MONARCH.
5) Guidance & Outlook / Investor Angle
- Full-year operational sales growth guidance increased to 6.5%-7.1%, with a projected midpoint of $100.6 billion.
- Adjusted operational EPS guidance raised to $11.50-$11.65, reflecting a 7.3% YoY growth.
- The company remains committed to returning capital to shareholders primarily through dividends, while maintaining a strong cash position of approximately $21 billion.
Bottom line: Johnson & Johnson's strong Q2 performance and raised guidance reflect a solid growth trajectory, driven by a diverse portfolio and innovative product launches, positioning the company favorably for long-term shareholder value.
Annual Reports, Presentations And IR Contacts
Go to the websiteJohnson & Johnson — Financial Overview, Stock Price, Market Cap
Johnson & Johnson is a company. Founded in 1886. As of October 9, 2026, the company's market capitalization is $618090745736 with a current stock price of $256.48.